Second greatest contributor to the Global Fund to Fight AIDS, Tuberculosis and Malaria, France has dedicated 5 % (ie. €18m per year) of its contribution to provide technical assistance to the Countries eligible to the Global Fund over the period 2011-2016 to support their access to and the implementation of the Global Fund grants.
The strategic evaluation of the 5 % Initiative, has been carried out by Technopolis France on behalf the French Ministry of Foreign Affairs, and has closely involved Expertise France, the 5 % implementing agency, the Global Fund teams, the French Ministry of Health and the Ministry of Research, Members of Parliament, and the civil society (NGOs). This evaluation had two objectives: providing evidence based on the relevance of the Initiative, its coherence with the own programmes of the Global Fund in the Countries, and on the outcomes and impacts of the technical assistance missions and projects funded by the 5 % Initiative ; delivering strategic orientations to the Ministry (and the stakeholders) regarding the future of the Initiative, that has been increased up to 7 % over the period 2017-2019 (ie. €25m per year).
The evaluation emphasizes the relevance of the Initiative with the current needs of the eligible Countries and its coherence with the Global Fund. It also notes positive signals regarding the outcomes and impacts of the intervention on the health system in the Countries. However, it also identifies some weakeness regarding the efficiency of the management of the Initiative.
The full report (in French) is available here: https://www.diplomatie.gouv.fr/fr/photos-videos-publications-infographies/publications/enjeux-planetaires-cooperation-internationale/evaluations/evaluations-2018/article/evaluation-strategique-de-l-initiative-5-2011-2016
A synthesis should be made available soon.
Effects of supplementary protection mechanisms for pharmaceutical products
To stimulate the development of new medicines, various forms of ‘supplementary protections’ exist that give companies extended monopoly rights. This includes: Supplementary Protection Certificates (SPCs), which prolong the patent protection for medicinal products by up to five years; paediatric extensions to SPCs; regulatory protection in the form of data and market exclusivity; as well as…View report
How can the EU Framework Programme for Research and Innovation increase the economic and societal impact of RDI funding in Finland?
Long-term objectives of Finnish research and innovation policy. One objective of the current government is to improve the quality and effectiveness of research and innovation. This study examines what kinds of benefits have been obtained from EU Framework Programmes and how Finnish participation can be further supported. Overall, the FP provides clear added value for…View report